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America's elderly is the fastest growing segment of our population and as a result, the 
demands on the health care system to provide C8re for these citizens have increased. Although 
part of this demand was met by the establishment of long term C8re facilities (skilled nursing 
homes), the quality of care provided by some of the early institutions was less than optimal. 
In the early 1970's, Townsend reported on nursing home problems in America. 1 Her text 
» 
effectively focused public attention on the potential inadequacies of nursing homes through the 
testimonials of the investigators, nursing home employees and the patients' families 
In June of 1974, the Department of Health, Education and Welfare approached this 
problem through their Long Term Care Facility Improvement Campaign.2 One component of 
this effort Involved the assessment of physician prescribing patterns In skilled nursing 
facilities. The stud/, a review of Medicaid records of 3458 patients, provided some 
interesting data. For example, each patient received an average of greater than six 
medications per dey. Major tranquilizers were the third most common class of drugs 
prescribed with 47* of all patients having at least one prescription for a tranquilizer. 
Finally, among the prescription medications most frequently prescribed, thioridazine ranked 
number three while chlorpromazine ranked number seven. These numbers indicate the volume 
of medications used by our nursing home geriatric population. The data also suggest that 
neuroleptics are frequently prescribed In this setting. Although a similar frequency of 
neuroleptic use has been observed by other authors, a wide variation has been reported 3 - 9 
(see Table 1). Differences in sampling techniques, reporting methods, types of institutions 
surveyed and physician prescribing habits mey account for the variability observed. Despite 
these differences, It is apparent that neuroleptics are frequently prescribed In the nursing 
home population. The indications for neuroleptics and the dosages prescribed, however, have 
not been evaluated. 
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Although eorly reports of neuroleptic misuse in nursing homes were anecdotal1 -1®, it is 
of interest that the current medical literature continues to Indicate a misuse potential.3,11 
Given the misuse potential of neuroleptics and the lack of studies which evaluate indications 
and dosages of neuroleptics, assessment of the following Is Indicated the Incidence of 
physician documentation of indications for neuroleptics, and the appropriateness of these 
indications and of the dosages prescribed. 
Many available studies report the diagnoses of nursing home patients. Some may note the 
incidence of neuroleptic use; however, no stud/ encountered reported the exact Indication for 
neuroleptics. Segal 8nd collegues 9 reported that 59* of the prescriptions in their survey of 
nursing home patients were without a documented indication. Unfortunately, the authors failed 
to define what constituted an indication. Nevertheless, documenting the need for neuroleptics 
by diagnosis or target symptoms is good medical practice. Documentation can be important 
not only from a medicolegal standpoint, but 8lso as a method to monitor and record responses to 
therapy. 
In addition to documenting the need fx treatment, the appropriateness of the indication 
must be considered. For instance, some patients ma/ be diagnosed as "senile" or as having 
organic brain syndrome (OBS). Organic brain syndrome is a nonspecific term encompassing 
a group of behavioral and psychological signs and symptoms without reference to a particular 
etiology. Most patients can be diagnosed more specifically with a particular organic mental 
disorder.'2 Furthermore, not all the symptoms associated with a diagnosis will respond to 
neuroleptic treatment. Although the sleep disturbances and hostility associated with senile 
dementia of the Alzheimer's type mo/ respond13,14, there are data demonstrating that 
memory, Insight and disorientation are not responsive.15,16 Indeed, the relative 
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responsiveness of various target symptoms has been addressed previously17 (see Figure). 
Thus, the target symptom(s) for which the patient is being treated ma/ be the best indicator 
of the need for neuroleptics 
Finally, the dosage prescribed is of interest. Although some studies have reported the 
average dose given 4 , no stud/ has commented on the appropriateness of the doses used in the 
nursing home setting. It is well documented that the eltterly have undergone marry physiologic 
changes which ultimately alter their response to neuroleptics18-20 (see Table 2). These 
changes include alterations in the pharmacokinetic distribution of these medications due to 
changes in the proportion of bod/ fat, water and muscle. Altered central nervous system (CNS) 
neurotransmitter concentrations and enzyme activities ma/ contribute to producing 
exaggerated responses to small doses of neuroleptics. A generally diminished capocity to 
metabolize and eliminate these compounds also make the elderly more sensitive to the 
therapeutic actions and to the side effects of these drugs. Since the normally recommended 
doses often are not appropriate for the aged population, many authors have suggested lower 
dosage ranges 2 1 " 2 5 
OBJECTIVES 
This stud/ has several objectives. The first is to report the Incidence of neuroleptic drug 
use in the geriatric nursing home population. The second is to report the incidence of 
physician documentation of the need for neuroleptics in geriatric nursing home patients. The 
third objective is to examine the indications fx neuroleptics and the dosages prescribed in 
light of two sets of criteria those developed by the National Institute of Mental Health (NIMH) 
and those assembled by the investigator. The indication criteria are listed in appendix I while 
the dosage criteria are in appendix II. 
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METHODS 
Data were collected by surveying two Salt Lake City area nursing homes, Alta Care (NH-1) 
aid Creekside Cere (NH-2). These homes do not specialize in psychiatry nor are they 
affiliated with the University of Utah Health Sciences Center (i.e. teaching, rotations for 
residents, interns or nurses, etc.) or with the Department of Pharmacy Practice at the 
» 
University of Utah. One hundred geriatric (65 years of age or older) patient charts were 
reviewed. Fifty patients from each nursing home were randomly sampled through the use of a 
random number table. The investigator (TGC) reviewed the charts for current orders for 
neuroleptics and the percentage of patients with an order (scheduled or pro re nata) was 
reported. Phenothiazines or other dopamine antagonists ordered specifically for nausea were 
excluded from analysis. 
Of the patients with an order for a neuroleptic, the percentage with a documented 
indication was noted. An indication could have taken the form of a diagnosis (and thus may have 
met the NIMH criteria) or a diagnosis and specific target symptoms (and thus may have met 
the target symptom based criteria). A discussion of these criteria is included in the following 
section. Since current diagnoses and target symptoms should be updated periodically, the 
search for an indication was limited to the information in the patient's current chart. Pro re 
nata (PRN) orders were examined for specific target symptoms indicating when a dose should 
be given and for defined dosing intervals and/or maximum dosages per specified time period. 
For ©cample, an order written as "Haldol® 2 mg prn agitation" was viewed as having a 
specific target symptom (agitation) but no dosing interval or maximum dosage per 24 hours. 
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Finally, the dosage of neuroleptics ordered per da/ for each patient was reviewed. The 
daily dose was defined as the total dose the patient could receive per da/ (i.e. scheduled plus 
PRN orders). Since the average number of doses allowed by those PRN orders specifying dosage 
intervals or dosage limits was 4.6, PRN orders without dosage limits were assigned four doses 
per da/. If the PRN neuroleptic was different from the scheduled neuroleptic, the PRN agent 
was converted to an equivalent dose of the scheduled"agent. Since the recommended daily doses 
were based on oral dosing, depot neuroleptics were converted to an approximate oral daily 
dosage equivalent. Although a very inexact procedure, this conversion was performed in an 
attempt to objectively evaluate the depot doses. Two methods were considered for fluphenazine 
m 
decanoate conversions and were derived from previous recommendations for converting oral to 
depot doses.17,26 These two methods are depicted below. 
weekly fluphenazine decanoate dose 
(1) = daily oral dose 
1.6 
(2) weekly fluphenazine decanoate dose = daily oral dose 
Only those fluphenazine decanoate doses which exceeded the dosing criteria regardless of the 
conversion method applied were reported. The method applied In converting haloperidol 
decanoate doses was 
monthly haloperidol decanoate dose 
- daily oral dose. 
15 
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Although current literature suggests that the monthly haloperidol decanoate dose ma/ vary 
from 10 to 20 times the daily oral dose,27-28 a ratio of 15:1 was recommended in the only 
geriatric stud/ encountered 2 9 and thus was employed in this stud/. All other parenteral doses 
were also converted to approximate oral equivalents50"33 (dosage equivalents are listed in 
Appendix III). The calculated daily dose was compared to the two criteria previously 
mentioned To assess the daily dose of neuroleptic the patient was actually receiving, the 
number of PRN doses received in the seven de/s prior to the survey was recorded. The actual 
daily doses received (scheduled plus received PRN doses) were then compared to the dosing 
criteria. Other dat8 collected included the patient's age, sex and diagnoses (for all patients 
reviewed). For those patients receiving neuroleptics, additional information gathered included 
target symptoms, neuroleptics ordered, dosing regimens prescribed and the prescribing 
physician. Descriptive statistics were used 1n analyzing the data 
CRITERIA 
Examination of the appropriateness of neuroleptic use requires an established 
standard so that an objective assessment can be made. In 1979, the NIMH in association with 
the American Psychiatric Association (APA) provided guidelines for establishing drug 
utilization review (DUR) programs and for conducting DUR studies in psychopharmacolog/21 
Contained in their monograph are criteria for neuroleptic use. Although these criteria were 
not created specifically for geriatric patients, the/ were employed because they contain 
diagnoses commonly seen in geriatric patients who are receiving neuroleptics. Since these 
criteria were developed in the late 1970's, some of the diagnoses are no longer recognized by 
the third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III). Thus, 
in addition to presenting the NIMH criteria as originally written, I have provided the 
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corresponding DSM-111 diagnoses for the outdated terms. The indications were also compared to 
criteria assembled by the investigator. These criteria were created since the NIMH guidelines 
are simply a list of diagnoses in which neuroleptic use is acceptable. However, a diagnosis is 
often not equivalent to an indication for use. In these instances, specific target symptoms 
should be documented Initially, this is performed to specify the need for neuroleptics. These 
symptoms (or remissions thereof) can then be documented periodically to assess the efficacy 
or the failure of neuroleptic treatments. The criteria which I have assembled, therefore, 
contain diagnoses and specific target symptoms which are responsive to neuroleptic agents. 
These criteria were compiled by reviewing recent literature14.22-24.34-37 (see appendix I). 
Similarly, the dosages prescribed were assessed using two criteria The first set of 
criteria was that provided by the NIMH in the monograph previously discussed Although these 
criteria contain specific recommendations for the elderly population, they only describe the 
doses as chlorpromazine equivalents. This is generally appropriate, but these equivalent 
dosages are only general guides. When higher doses of the high potency neuroleptics are used, 
differences in the agents appear as demonstrated by the tolerability of side effects. For 
example, although SOmg of haloperidol is equivalent to 3000mg of chlorpromazine, this 
amount of chlorpromazine would cause intolerable side effects in almost all patients. Thus, at 
higher doses chlorpromazine equivalents lose some validity. By reviewing recent literature 
and texts 2 2 - 2 5 that specifically focus on geriatric psychopharmacology, I have assembled B 
second set of criteria for neuroleptic dosing in the elderly. These criteria, constructed by 
using the highest and the lowest recommended doses from the sources reviewed, are based upon 
individual neuroleptic agents (see appendix II). 
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RESULTS 
From September 15,1986 to October 19,1986, fifty patient charts from each of the 
two nursing homes were reviewed providing a total of 100 charts. General information 
regarding patient age, sex, diagnosis and the incidence of neuroleptic prescribing is shown in 
Table 3. Although 57* of patients had orders for neuroleptics, only 40* of the total 
population received these medications. This difference reflects the 17 patients who only had a 
i 
PRN order, but did not receive any doses. 
Of the 57 patients with an order for a neuroleptic agent, seven patients (12*) were 
without a documented indication according to the NIMH guidelines compared to 32 patients 
(56*) who did not conform to the target symptom inclusive criteria. These exceptions to the 
criteria ere noted in Table 4. 
Calculation of the total possible daily dose revealed that 23 of the 57 orders (40*) 
written exceeded the NIMH criteria for geriatric prescribing while 16 of the 57 orders 
(28*) exceeded the criteria based on individual neuroleptics. These high percentages reflect a 
proclivity to write PRN orders without maximum dosage limits (see below). Examination of 
the dosages actually received shows that ten of 57 patients (18*) received doses in excess of 
the NIMH criteria while seven of 57 patients (12*) received doses which were greater than 
the recommended doses based on specific agents. Table 5 summarizes these excesses in dosing. 
Forty-seven PRN orders were written for 44 patients. Of these 47 orders, ten 
(21 * ) did not indicate symptom(s) for which a PRN dose should be given. Nine orders (19*) 
did not contain any dosage limit per 24 hours or did not specify a dosage interval. One order 
was written for an inappropriate indication (confusion). Overall, 18 of 47PRN orders 
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(38*) were either without a specific Indication or without dosage limits. Finally, of the 44 
patients with PRN orders, only five had received any PRN doses in the week prior to the stud/ 
DISCUSSION 
» 
This study reveals discrepancies between what the NIMH published as appropriate 
indication and dosing guidelines for neuroleptics fn the elderly and what was observed in the 
study population. However, the NIMH recommendations are only guides and deviations sre not 
synonymous with inappropriate prescribing. Rather, the guidelines serve as a tool for 
identifying potentially Inappropriate prescribing patterns. Determining the appropriateness 
or inappropriateness of prescribing patterns W8S not the purpose of this stud/ and will not be 
addressed. Discrepancies between the criteria of the NIMH versus those crested by the 
investigator are discussed below. 
The largest discrepancy between these criteria was in the area of indications. Although 
only seven patients were without proper diagnostic indications per the NIMH list, this number 
of patients is a substantial percentage (12*) of the population with neuroleptic orders. 
Encephalopathy of various origins, cerebrovascular accident and personality disorder 
accounted for five of these patients while the other two had no diagnosis resembling any 
psychiatric or neurologic disorder (see Table 4). Requiring documentation of target symptoms 
increased the number of patients without proper indications to 32 (56*). Most of these 
patients had a diagnosis of OBS, a term refering to a group of psychological and/or behavioral 
symptoms. Thus, documenting target symptoms would aid in defining what is being treated as 
well as providing crucial information to document the success or failure of neuroleptic 
treetments. In addition, since only some of the symptoms of OBS are known to respond to 
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neuroleptic agents, documenting appropriate symptoms would further support the use of 
neuroleptics. Five patients with OBS had symptoms recorded which typically do not respond to 
these medications (confusion or depression). This may not mean that neuroleptic use was 
inappropriate, but rather that the symptoms being treated are not adequately documented. 
Finally, one patient with a history of schizophrenia had no symptoms recorded Current target 
symptoms in this patient which are responsive to neuroleptic treatment should be documented. 
The diagnosis of schizophrenia alone is not a sufficient indication for neuroleptic use. In fact, 
some authors state that since neuroleptics do not alter the course of schizophrenia, these 
agents should be discontinued in the absence of target symptoms to prevent or delay serious 
adverse effects such as tardive dyskinesia.38"40 An additional note regarding documentation of 
« 
symptoms is that 12 cases without documented target symptoms had the appropriate symptoms 
recorded in the nurses notes in their charts. Although charting of this information by nurses 
is important and valuable, physicians may also want to document target symptoms periodically 
since these symptoms are subjective in nature. In summary, 12* of patients were without 
NIMH indications while 56* of patients did not have symptoms documented to support the use 
of neuroleptics. Adopting the practice of documenting target symptoms may be an important 
step in identifying those patients who do not need neuroleptic therapy and thus may avoid the 
cost and the potential side effects associated with these agents. 
The number of patients receiving neuroleptics in excess of the dosing criteria was 
similar whether using the NIMH criteria or the criteria based on individual neuroleptics. 
While 23 orders (40*) were written in excess of the NIMH criteria for daily doses and 16 
orders (28*) exceeded the criteria based on individual neuroleptics, these numbers are 
misleading since they are merely a reflection of excessive PRN prescribing. These numbers 
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fall to ten (18*) and seven (12*) respectively when we only consider those patients who 
actually received excessive daily doses (see Table 5). The major difference between the two 
sets of dosage criteria is that the criteria based on individual agents allow for higher dosing of 
the high potency neuroleptics such as fluphenazine and haloperidol. Equivalent doses of the low 
potency agents, chlorpromazine and thioridazine, often would be intolerable due to their 
anticholinergic, sedative and hypotensive effects. ThuS, while the NIMH criteria identified 
more patients with potentially high doses, all of theee cases involved either fluphenazine or 
haloperidol. Although both sets of criteria identified a similar number of patients receiving 
excessive doses, criteria based upon individual agents would be more rational since 
chlorpromazine equivalents do not consider the different side effect profiles of these agents. 
Pro re nata prescribing habits also deserve comment. Twenty-one percent of the PRN 
orders did not specify the symptom(s) for which the order was written. The potential for 
inappropriate interpretation of these orders is great41-42 Target symptoms in PRN orders 
need to be identified as clearly as possible since they are often subjective and may be 
mislabeled by an untrained eye. Nineteen percent of PRN orders were without maximum dosage 
limits or specified dosage intervals. Although this did not result in overmedication for any 
patient in these homes, physicians need to write these orders such that dosage limits and 
intervals are obvious, thereby circumventing potentially Inaccurate interpretations or 
overdosing Finally, since 39 of the 44 patients with PRN orders (88*) had not received any 
of these "as needed" doses, one may question the need for the orders. Mason and DeWolfe 4 3 
have commented on the almost automatic continuation of PRN orders once written and the need 
to review these orders periodically. In summary, almost 40* of PRN orders were typified by 
incomplete and unclear prescribing although no patient appeared to be overmedicated as a 
direct result 
12 
A procedural problem encountered in this stud/ involved finding dosage guidelines for 
the depot neuroleptics In the elderly. Only recently through the development of sensitive drug 
asss/s and the application of pharmacokinetic principles have oral to depot dosage guidelines 
appeared for the youngBr adult. Much of the previous data was based upon retrospective 
analyses of empiric trials. The difficulties in obtaining reliable conversions from oral to depot 
dosage forms testify to the complexity of Interfacing these two very different pharmacokinetic 
situations. Patient specific parameters such as liver disease or smoking further complicate 
this conversion. Age-related changes in first-pass metabolism, distribution and elimination 
as well as possible changes in intramuscular absorption rates create the need to perform 
pharmacokinetic studies of depot neuroleptics in the elderly. These studies have not been 
done. Only three articles were encountered which recommend dosages of depot neuroleptics 
for the elderly2 0 , 2 8 , 2 9 However, since pharmacokinetic studies are generally lacking in 
this population, I decided to convert the depot doses to a daily oral dose realizing the methods 
for this conversion are not accurate. 
Finally, two limiting factors concerning inferential statements based on this study 
should be noted. The first is that only two nursing homes were surveyed; thus, the nursing 
home sample was small. The second is that only one physician was responsible for 90SB of all 
prescribing in this stud/. Nevertheless, I feel that the prescribing patterns are not unique and 
should be verified by further studies. 
Through the course of this study, other problems requiring research have been 
identified Given that 88* of the patients with PRN orders in our study did not receive any of 
their "as needed" doses in the week prior to the survey, a retrospective study of PRN orders 
would reveal when the orders originated and if any doses had been given. A potential problem 
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with long standing PRN orders for neuroleptics is that a patient receiving neuroleptics from 
an old order may have other etiologies for his or her symptoms. For example, agitation in a 
normally calm geriatric patient may be the only symptom of pneumonia, sepsis or an 
intracranial lesion. Thus, return of agitation requires a proper diagnosis prior to treatment. 
The potential for inaccurate interpretations of PRN orders should also be addressed One 
approach would involve assessing when nurses would give neuroleptics to a patient given a 
case stud/ and a PRN order, with or without target symptoms specified. The impact of target 
symptom documentation could also be evaluated For example, a program for physicians 
regarding target symptom documentation proceeded and followed by a stud/ similar to this one 
would reflect any changes in prescribing patterns or in the incidence of neuroleptic use in the 
nursing home patient population. Finally, an extension of this stud/ could assess the 
appropriateness or inappropriateness of indications and dosing of neuroleptics in the elderly. 
These studies would be valuable in reporting the percentage of patients who are 
inappropriately treated with neuroleptics rather than simply reporting the percentage who 
exceed a given criteria These studies would also validate our current dosage recommendations 
for the elderly or ma/ suggest that our current recommendations are unnecessarily too 
limiting or too liberal. 
SUMMARY 
This stud/ demonstrated that a number of patients (12*) were prescribed 
neuroleptics without an indication which conforms to NIMH guidelines. Fifty-six percent of 
patients did not have appropriate target symptoms documented to support neuroleptic therapy. 
Adopting and employing criteria which contain target symptoms is recommended since this 
14 
will aid in documenting responsiveness to therapy as well as identifying those patients who 
ma/ not benefit from therapy. 
Twelve to eighteen percent of patients were receiving neuroleptic doses in excess of a 
criteria based upon individual agents and the NIMH criteria respectively. A set of criteria 
baaed upon individual agents is suggested to be more rational since the NIMH criteria (based 
upon chlorpromazine equivalents) do not reflect the different side effect profiles of the 
neuroleptics. 
Finally, 38* of all PRN orders were written either without identifying a target 
symptom for use or without dosage intervals or maximum dosage limits. Attention to these 






INCIDENCE OF NEUROLEPTIC USE 
IN GERIATRIC POPULATIONS 
PATIENT SAMPLE AGE (yrs) N % ON NEUROLEPTICS REF * 
Medicare/ Medicaid 
nursing home patients 
Medicaid recipients in 
173 Tennessee 
nursing homes 
Twelve VA hospitals; 
mental illness primary 
diagnosis 
One nursing home 
New York City 
nursing home 
Nursing home residents 
transferred from one 
hospital 




























One nursing home >60 50 86 
Abbreviations: N = number of patients in study 
Ref ** = reference number 
TABLE 2 17 
AGE-RELATED CHANGES & THEIR CLINICAL 
& PHARMACOLOGICAL CONSEQUENCES* 
FACTOR CHANGE CONSEQUENCE 
DISTRIBUTION 
PLASMA ALBUMIN 
FIRST PASS EFFECT 
• INCREASE IN FAT:MUSCLE 
RATIO INCREASES Yd OF 
FAT SOLUBLE DRUGS 
• OFTEN DECREASES DUE 
TO POOR NUTRITION 
• ALL PSYCHOTROPICS ARE FAT 
SOL UB L E; I NCR EASE D Yd MAY 
PROLONG CLEARANCE 
• HYPOALBUMINEMIA HAS BEEN 
ASSOCIATED WITH INCREASED 
TOXICITY IN THE ELDERLY 
• DECREASES WITH AGE • THEORETICALLY INCREASES 
& CHF BIOAVAILABILITY OF DRUGS WITH 
• DECREASED BY ' HIGH EXTRACTION RATIO (E.G. 
PROPRANOLOL &CIMETIDINE CHLORPROMAZINE) 




• MAY PROLONG EXCRETION OF DRUGS 
DEMETHYLATED BY LIYER(E.G. 
THIORIDAZINE & IMIPRAMINE) 
• IMPAIRED OR DELAYED 
MEATBOLISM OF TCA'S AND MANY 
PHENOTHIAZINES 
• PROLONGED TIME TO REACH STEADY 
STATE OF ABOYE DRUGS 
EXCRETION • DECREASE IN RENAL 
BLOOD FLOW, GFR, 
RESORPTIVE & EXCRETORY 
CAPACITIES OF TUBULES 
• REDUCTION IN RENAL CLEARANCE 
OF DRUGS SUCH AS LITHIUM 




• AGE RELATED CNS TOXICITY • INCREASED CONFUSION WITH 
TO LITHIUM? LITHIUM 
• INCREASED SENSITIVITY 
TO BENZODIAZEPINES 
• DECREASE IN NIGRO-
STRIATAL DOPAMINE 
• DECREASE IN CNS 
CHOLINERGIC FUNCTIONING 
• INCREASED SEDATION, CONFUSION, 
& DISINHIBITION WITH 
BENZODIAZEPINES 
• INCREASE IN EPS WITH 
NEUROLEPTICS 
• INCREASED SENSITIVITY TO 
ANTICHOLINERGIC PROPERTIES OF 
PSYCHOTROPIC DRUGS; TOXIC 
CONFUSIONAL STATES MAY OCCUR 
ABBREVIATIONS: Yd=YOLUME OF DISTRIBUTION, CHF=CONGESTIYE HEART FAILURE, 
GFR=GLOMERULAR FILTRATION RATE,EPS=EXTRAPYRAMIDAL SYMPTOMS,TCA"S=TRICYCLIC 
ANTIDEPRESSANTS, CNS=CENTRAL NERVOUS SYSTEM 




GENERAL PATIENT INFORMATION 
& INCIDENCE OF NEUROLEPTIC PRESCRIBING 
NURSING HOME * 1 NURSING HOME * 2 TOTALS 
NUMBER OF PATIENTS 50 50 100 
SEX- MALE 17 19 36 
FEMALE 33 31 64 
AVERAGE AGE (yrs) 78.8 79.9 79.4 
(range 65-95) (range 65-97) 
PSYCHIATRIC DIAGNOSIS-
OBS 28 33 61 
SCHIZOPHRENIA 6 4 10 
PERSONALITY DISORDER 0 1 1 
ENCEPHALOPATHY* 2 1 3 
CVA* 1 0 1 
NONE 13 11 24 
NUMBER WITH ORDER 
FOR NEUROLEPTICS 33 24 57 
•Although not psychiatric diagnoses, these were included since they appeared to be 
the only reason for neuroleptic use In these patients. 
Abbreviations: OBS= Organic brain syndrome 
CVA= Cerebrovascular accident 
TABLE 4 
NONCONFORMING INDICATIONS FOR NEUROLEPTICS 
NIMH CRITERIA ( * ) DIAGNOSIS/ TARGET SYMPTOM CRITERIA ( * ) 
OBS/ No target symptoms (19*) 
Encephalopathy (3) Encephalopathy/ No target symptoms (3) 
Cerebrovascular accident (1) Cerebrovascular accident/ Very senile (1) 
Personality disorder (1) Personality disorder/ Agitation, anxiety (1) 
OBS/ Confusion (3) 
OBS/ Confusion,depression (1) 
OBS/ Depressed, labile affect (1) . 
History of paranoid schizophrenia/ No target symptoms (1) 
No psychiatric diagnosis (2) No psychiatric diagnosis/ Agitation (1) 
No psychiatric diagnosis/ Confusion, poor memory (1) 
TOTALS 7 (12S ) 32 (56%) 
* If one includes nurses notes as a source of target symptom documentation, 12 of these 
cases would meet the criteria reducing the total number without Indications to 
20 (35*). 
Abbreviations: 0BS= Organic brain syndrome 
NIMH= National Institute of Mental Health 
20 
TABLE 5 
DOSAOES RECEIVED IN EXCESS OF CRITERIA 
(MG/DAY) 
PATIENT CASE: CRITERIA * 1* CRITERIA *2* 
DIAGNOSIS/ TARGET SYMPTOM(S) NIMH (CPZ EQUIVALENTS) INDIVIDUAL AGENTS 
OBS/ Agitation 10OOmg 
Schizophrenia/ Flat affect 500mg 
Dementia/ No symptoms documented 750mg 
Schizophrenia/ Hostility, agitation 
Paranoid schizophrenia, residual type/ 2000mg 
Sleep disturbance, poor grooming 
Dementia/ Sundowning, agitation 650mg 
Dementia/ Hallucinations, aggression 600mg 
OBS/ Inappropriate behavior, confusion 500mg 
OBS/ No symptoms documented 390mg 
History of paranoid schizophrenia/ 490mg 
No symptoms documented 
OBS/ No symptoms documented 300mg 
Haloperidol 20mg 
Thioridazine 350mg 
& Perphenazine 12mg 
Haloperidol 15mg 
Thioridazine 350mg 
Haloperidol 30mg & 
Chlorpromazine 500mg 
Haloperidol 11mg 
& Thioridazine tOOmg 
Haloperidol 12mg 
Percentage of all 57 orders (100* ) 
exceeding criteria 
10 (18* ) 7 ( 1 2 * ) 
Abbreviations: NIMH= National Institute of Mental Health 
CPZ= Chlorpromazine 
OBS= Organic brain syndrome 





Combativeness and hostility 
Tension and hyperactivity 
Hallucinations 
, Sleep disturbances 
Appetite 
Dress or grooming 
Delusions 






RELATIVE RESPONSIVENESS OF 
TARGET SYMPTOMS TO NEUROLEPTIC THERAPY 
From: Ereshefsky L, Stimmel GL. Psychosis. In: Katcher BS, Young LY, Koda-
Kimble MA eds. Applied therapeutics: The clinical use of drugs 3rd ed. 




NEUROLEPTIC DRUG USE CRITERIA 
National Institute of Mental Health Criteria* 
(a)Psychotic Disorders: 
-schizophrenia 
-organic brain syndrome**!OBS]' 
-manic depressive illness (Bipolar disorder) 
-psychotic depression (Major depression with psychotic features) 
-Involutional melancholia (Major depression) 
(b)Nonpsychotic Disorders 
-any neurosis*** in a patient with: 
-failure to respond to benzodiazepines 
- undesirable response to benzodiazepines 
-history of abusing sedatives/tranquilizers 
-pronounced suspiciousness .irritability,mood lability or agitation 
-psychophysiological disorders (Psychological factors affecting physical 
conditions) 
-organic brain syndrome without psychosis 
-mental retardation with severe behavioral disturbance 
-minimal brain d/sfunction (Attention deficit disorder) 
-manic depressive illness .depressive type (Bipolar disorder, depressed); 
only after failure with the antidepressants and the monoamine oxidase 
inhibitors 
* DSM-111 equivalent diagnoses shown in parentheses. 
**0BS is recognized by the DSM-III. In thiscl8ss of disorders, more specific diagnoses 
are found such as dementia, delirium, intoxication, withdrawal, organic hallucinosis, 
organic delusional syndrome, amnestic syndrome, organic affective syndrome and 
organic personality syndrome. 
***Neurosis is no longer recognized as a diagnosis by the DSM-III. DSM-III lists 
affective, anxiety, somatoform, dissociative, and psychosexual disorders as those 
which commonly have neurotic symptoms. 
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3. Paranoid Disorder 
(Late Paraphrenia) 
4. Agitated Depression 
5. Bipolar Disorder 
TARGET SYMPTOMS 
delusional thinking, hallucinations, 
disorganized thinking, paranoia, poor 
grooming, hostility, aggression, sleep 
disturbances, decreased appetite, blunted or 
inappropriate affect, social withdrawal 
anxiety, wandering, restlessness, agitation, 
paranoia, belligerence, hostility, sleep 
disturbances, sundowning (increase in 
symptoms at dusk) 
paranoia, agitation, irritability, insomnia, 
hallucinations 
insomnia, pacing, loss of appetite, suicidal 
thoughts, agitation gestures (e.g. pulling 8t 
hair or clothes) 
acute manic symptoms such as insomnia, 
pressured speech, hyperactivity, decreased 
appetite, delusions, hallucinations, hostility, 
flight of ideas or racing thoughts 
•Abbreviations: 
SDAT= senile dementia of the Alzheimer's type 
OBS- organic brain syndrome 
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APPENDIX II 
RECOMMENDED DOSAGES FOR 
NEUROLEPTICS IN THE GERIATRIC PATIENT 
I. National Institute of Mental Health Criteria (chlorpromazine equivalents) 
(a) For psychotic disorders: 
25-400mg (non-OBS patients) 
10-200mg (OBS patients) 
(b)For nonpsychotic disorders: 
25-200mg (non-OBS patients) 
lO-IOOmg (OBS patients) 
Criteria based on individual agents 











Abbreviations: 0BS= Organic brain syndrome 
APPENDIX III 
NEUROLEPTIC DOSAGE EQUIVALENTS 
NEUROLEPTIC EQUIVALENT DOSAGE (MQ) 










INTRAMUSCULAR TO ORAL DOSAGE EQUIVALENTS 
NEUROLEPTIC INTRAMUSCULAR ORAL 
Chlorpromazine 1 4 
Mesoridazlne 1 2 
Thiothixene 1 2 




1. Townsend C. Old age -The last segregation. New York: Grossman Publisher 1971: 
110-122. 
2. U.S. Department of Health Education & Welfare. Physician's drug prescribing patterns in 
skilled nursing facilities. Long term care facility improvement campaign, Monograph No. 
2. Washington D.C.:U.S. Government Printing Office 1976. 
3. Ray WA, Federspiel CF, Schaffner W. A stud/ of antipsychotic drug use in nursing homes: 
Epidemiologic evidence suggesting misuse. Am J Public Health 1980;70:485-491. 
4. Prien RF, Haber PA, Caffey EM. The use of psychoactive drugs in elderly patients with 
psychotic disorders. Survey conducted in 12*VA hospitals. J Am Geriatr Soc 1975;23. 
104-117. 
5. Ingman SR, Lawson IR, Pierpauli PG, Blake P. A survey of the prescribing and 
administration of drugs in a long term care Institution for the elderly. J Am Geriatr Soc 
1975;23:309-316. 
6. Mann AH, Jenkins R, Cross PS, Gurland BJ. A comparison of the prescriptions received by 
the elderly in long-term care in New York 8nd London. Psychol Med 1984;14:891-897. 
7. Reynolds MD. Institutional prescribing for the elderly: Patterns of prescribing in a 
municipal hospital aid a municipal nursing home. J Am Geriatr Soc 1984;32:640-645. 
8. Salzman C, Van Der Kolk B. Psychotropic drug prescriptions for elderly patients in a 
general hospital. J Am Geriatr Soc 1980;28:18-22. 
9. Seg8l JL, Thompson JF, Floyd RA. Drug utilization 8nd prescribing patterns in a skilled 
nursing facility: The need for a rational approach to therapeutics. J Am Geriatr Soc 
1979; 27:117-122. 
10. Moss FE, Halamadaris YJ. Too old, too sick, too bad. Germantown MD: Aspen Systems 
Corporation 1977. 
11.Waxman HM, Klein M, Carner EA. Drug misuse in nursing homes: An institutional 
addiction? Hosp Community Psychiatry 1985;36:886-887. 
12. Barnes RF, Raskind MA. DSM-111 criteria and the clinical diagnosis of dementia: A nursing 
home stud/. J Gerontol 1981;36:20-27. 
13. Cowley LM, Glen RS. Double blind stud/ of thioridazine and haloperidol in geriatric 
patients with a psychosis associated with organic brain syndrome. J Clin Psychiatry 
1979;40:411-419. 
14. Barnes R, Yelth R, Okimoto J, et al. Efficacy of antipsychotic medications in behaviorally 
disturbed dementia patients. Am J Psychiatry 1982; 139:1170-1174. 
30 
15. Tsuang MM. Lu LM. Stotsky BA. Cole JO. Haloperldol versus thioridazine for hospitalized 
paychogeriotric patients: Double-blind stud/. J Am Geriatr Soc 1971 ;19:593-600. 
16. R8sk1nd MA, Storrle MC. The organic mental disorders. In: Busse EW, Blazer DO eds. 
Handbook of geriatric psychiatry. New York: Van Nostrand Reinhold Co. 1980: 314-319. 
17. Ereshefsky L, Stimmel GL. Psychosis. In: Katcher BS, Young LY, Koda-Kimble MA eds. 
Applied therapeutics: The clinical use of drugs 3rd ed. Spokane Applied Therapeutics Inc. 
1983;985-1016. 
18. Salzman C. Pharmacokinetics of psychotropic drugs and the aging process. ln:Sa1zman C. 
ed. Clinical geriatric psychopharmacolog/. New York: McGraw-Hill 1984;32-45. 
19. Salzman C. A primer on geriatric psychopharmacoloq/. Am J Psychiatry 1982; 139:67-
20. Raskow DE. Antipsychotic medication and the elderly. J Clin Psychiatry I985;46(5,sec 
2): 36-40. 
21. Towery OB, Brands AB eds. Psychotropic drugs: Approaches to psychoph8rmacologic drug 
use. Rockville MD:U.S. Dept. of Health, Education & Welfare and the National Institute of 
Mental Health 1979. DHEW Publ. no. (ADM)79-758., 
22. Vestal RE.Drug treatment in the elderly. Boston: ADIS Health Science Press 1984; 
Chapter 23:318-337. 
23. Spira N, Dysken MW, Lazarus LW, Davis JM, Salzman C. Treatment of agitation and 
psychosis. In: Salzman ed. Clinical geriatric psychopharmacolog/. New York: McGraw-Hill 
1984:49-76. 
24. Thompson TL, Moran MG, Nies AS. Psychotropic drug use in the elderly. N Engl J Med 
1983;308:194-199. 
25.Bre3sler R. Neuroleptic agents. In: Conrad KA, Bressler R eds. Drug therapy for the elderly 
St. Louis: CY MosbyCo. 1982:277-294. 
26. Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR. Future of depot 
neuroleptic therapy: Pharmacokinetic aid pharmacodynamic approaches. J Clin 
Psychiatry I984;(5,sec 2):50-59. 
27. Nalr NPV, Suranyl-Cadotte B, Schwartz G, Thavundeyil JX, Achim A, Lizondo E, Nayak R. A 
clinical trial comparing intramuscular haloperidol decanoete and oral haloperidol in 
chronic schizophrenic patients: Efficacy, safety and dosage equivalence. J Clin 
Psychopharmacol 1986; 6:30s- 37s. 
28. Jann MW, Ereshefsky L. Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. 
Clin Pharmacokinet 1985;10:315-333. 
29. Viukari M, Salo H, Lamminsivu U, Gordon A. Tolerance and serum levels of haloperidol 
during parenteral and oral haloperidol treatment in geriatric patients. Acta Psychiatr 
Scand 1982;65:301-308. 
31 
30. Biannchetti G, Poirier-Littie MF, Morselli PL, Deniker P. Influence of route of 
administration on haloperidol plasma levels in psychotic patients. Int J Clin Pharmacol 
Ther 1980;18:324-327. 
31. Dahl SG, Strandjord RE. Pharmacokinetics of chlorpromazine after single aid chronic 
dosage. Clin Pharmacol Ther 1977;21:437-448. 
32. Gershon S, Sakalls G, Bowers PA. Mesorldazlne-A pharmacodynamic and pharmacokinetic 
profile. J Clin Psychiatry 1981 ;42:463-469. 
33. Olln BR, ed. Facts8ndcomparisons. JB Lippincott:St Louis, Mo 1986. 980-988. 
34. Maletta GJ. Use of antipsychotic medications in-the elderly. Ann Rev Gerontol Geriatr 
1984;4:175-220. 
35. Hollister LE. Alzheimer's disease: Is it worth treating? Drugs 1985;29:483-488. 
36. Erwin WG. Senile dementia of the Alzheimer's type. Clin Pharm 1984;3:497-504. 
37. Salzman C. Management of psychiatric problems. In: Rowe JW, Besdine RW eds. Health and 
disease in old age. Boston: Little, Brown & Co. 1982:115-121. 
38. Carpenter WT Jr, Heinrichs DW. Early intervention, time-limited, targeted 
pharmacotherapy of schizophrenia. Schizophr Bull 1983;9:533-542. 
39. Schooler NR, Levine J. Strategies for enhancing drug therapy of schizophrenia. Am J 
Psychother 1983;37:521-532. 
40. Heinrichs DW, Carpenter WT Jr. Experience with a drug-free month in schizophrenic 
outpatients. Psychopharmacol Bull 1985 ;21:117-119. 
41. Howard JB, Strong KE Sr., Strong KE Jr. Medication procedures in a nursing home: Abuse 
of PRN orders. J Am Geriatr Soc 1977;25:83-84. 
42. Ayd FJ. Problems with orders for medication as needed. Am J Psychiatry 1985; 142: 
939-942. 
43. Mason AS, DeWolfe AS. Usage of psychotropic drugs in a mental hospital: I. As needed 
(PRN) antipsychotic medications. Curr Ther Res 1974;16:853-860. 
CURRICULUM VITAE 
THOMAS GERARD CANTU' 
Date of birth: March 15, 1960 Place of birth: San Antonio, Texas 
EDUCATION 
University of Utah 
College of Pharmacy 
Salt Lake City, Utah 
Degree: Doctor of Pharmacy, 1987 
University of Texas at Austin 
College of Pharmacy 
Austin, Texas 
Degree: Bachelor of Science in Pharmacy, 
1985 
Amarlllo Jr. College 
College of Liberal Arts 
Amarillo, Texas 
Degree: None; Psychology major, 1978-1980 
TRAINING 
Clinical Pharmacy Residency, 1987 
University Hospital Health Sciences Center 
Salt Lake City, Utah 
HONORS RECEIVED 
Ewart A. Swlnyard Scholarships 
University of Utah, 1986, 1987 
Graduation with Highest Honors 
University of Texas at Austin, 1985 
Endowed Presidential Scholarship 
University of Texas at Austin, 1984 
Outstanding Basic Sciences Student 
University of Texas at Austin, 1985 
Dean's Honor List 
University of Texas at Austin, 1980- 1985 
Abbott Laboratories I ntership, 1984 
Selected by Texas Society of Hospital 
Pharmacists 
